Antiviral Drugs Market Projected to Hit $125.26 Billion by 2035
Event summary
- Global antiviral drugs market valued at $77.93 billion in 2025, projected to reach $125.26 billion by 2035, with a CAGR of 4.86%.
- North America held the largest regional share at 47.0% in 2025, while Asia Pacific is expected to record the fastest growth at 6.08% annually.
- HIV medicines represent 58.0% of indication revenue, with combination therapy comprising 62.0% of revenue.
- Key players include Gilead Sciences, GSK / ViiV Healthcare, Merck & Co., Pfizer, Shionogi, Cipla, Aurobindo Pharma, Dr. Reddy's Laboratories, and Sun Pharmaceutical.
The big picture
The antiviral drugs market is driven by the continuing need for HIV treatment, chronic hepatitis management, and emerging respiratory indications. The shift toward long-acting HIV prevention and more convenient treatment combinations is reshaping the market landscape. North America's dominant share and Asia Pacific's rapid growth highlight regional opportunities and access constraints that affect revenue.
What we're watching
- Regulatory Approvals
- The pace at which new long-acting HIV prevention and streamlined regimens gain regulatory approvals will shape market dynamics.
- Generic Competition
- Whether patent expiries and tendering will accelerate generic competition in mature HIV and hepatitis medicines.
- Regional Growth
- How the Asia Pacific region's 6.08% modeled CAGR will impact global market shares and revenue distribution.
Related topics
